Plateaued on Ozempic: Is Switching to Mounjaro the Answer?

There is real head-to-head evidence that tirzepatide outperforms semaglutide. In the SURMOUNT-5 trial, published in the New England Journal of Medicine, 751 adults with obesity and without type 2 diabetes were randomised to one drug or the other. After 72 weeks, the tirzepatide group lost 20.2% of body weight versus 13.7% on semaglutide.

That's a substantial difference, and it's the number every article about switching quotes. But there's a problem with using it to answer your question, and almost nobody says it out loud:

SURMOUNT-5 compared starting on one drug versus starting on the other. It did not study people who plateaued on semaglutide and then switched. Those are different questions, and the trial answers the first one.

Why that distinction matters

If tirzepatide produces more weight loss on average, it's reasonable to think someone stalled on semaglutide might do better on it. That's a sensible hypothesis. It is not the same as evidence.

The people in the tirzepatide arm of SURMOUNT-5 had 72 weeks on that drug from the start. Someone switching after a year on semaglutide is in a different physiological situation: lower starting weight, reduced energy requirements, and a body that has already adapted to substantial weight loss. The 20.2% figure was not measured in that population, and shouldn't be read as a prediction for it.

Be particularly careful with articles quoting precise switching statistics — specific percentages of patients who "broke through" a plateau by a specific week. Several of the pages ranking for this query cite figures we could not trace to any published trial. If a number doesn't name a study you can look up, treat it as marketing.

First: is it actually a plateau?

Before the question is "which drug," it's worth establishing that something is genuinely wrong. Often it isn't.

Weight loss is supposed to slow. A smaller body needs less energy. The deficit that produced steady loss at the start produces less loss later, at the same intake. A curve that flattens after months of loss is the expected shape, not a malfunction — the physiology is covered in the plateau playbook.

Things to rule out before concluding the medication has stopped working:

That last row is worth dwelling on. If the scale is flat but your clothes fit differently, the thing that's stalled may be a number rather than your progress — which is exactly why we argue for tracking body composition rather than weight alone.

What switching actually involves

If you and your prescriber do decide to change, some practical realities:

You start at the bottom again. Tirzepatide begins at 2.5 mg once weekly regardless of what semaglutide dose you were on. There is no dose equivalence and no conversion factor between the two — they're different molecules, and tirzepatide acts on both GIP and GLP-1 receptors while semaglutide acts on GLP-1 alone. Anyone offering you a conversion chart between them is inventing it. Our dose conversion guide explains why these charts don't mean what people think.

You re-climb the ladder. From 2.5 mg, titration proceeds in scheduled steps. Reaching a maintenance dose takes months, and each step restarts the 4-to-5-week accumulation described in when appetite suppression kicks in. Plan for the transition period to be a step backwards before it's a step forwards.

Side effects come back. Tolerance you built on semaglutide doesn't transfer. Expect a repeat of early-dose GI effects — see when side effects peak.

Timing is your prescriber's call. The two drugs have different half-lives, semaglutide clears slowly, and the two should not be taken together. How to sequence the transition is a clinical decision, not something to work out from a forum thread.

Access and cost may decide it anyway. Formulary coverage, supply, and whether you're being treated for weight management or type 2 diabetes often constrain the choice more than efficacy data does. In the UK, NHS versus private routes differ substantially — the UK comparison covers that ground.

What to bring to the conversation

A prescriber deciding whether to switch you needs to distinguish "this has genuinely stopped working" from "this is a normal slowdown." You can make that easy:

• Weight over time, weekly at a consistent time — the trend, not individual readings
• Current dose and how long you've been on it
• When the loss actually stopped, as a date
• Protein intake on a typical day
• Side effects you're still getting, or have stopped getting
• Body composition if you have it — the single most useful thing for showing whether "no weight change" means "no change"

Six months of that is a far stronger case than "I think I've plateaued." It also protects you from the opposite error: switching away from a drug that was still working.

The honest summary

Tirzepatide produced more weight loss than semaglutide in a well-conducted head-to-head trial. That's real. Whether switching after a plateau reproduces that advantage is not well established, and the confident numbers circulating on this topic mostly aren't traceable to published research.

Switching is a legitimate option that helps some people. It's also months of re-titration, a return of side effects, and no guarantee. That trade-off is worth making deliberately, with your prescriber, after ruling out the more common explanations — not because a plateau felt like failure.

What to try before switching

Switching means months of re-titration. Several things are worth exhausting first, because they're faster and they address causes a different drug wouldn't fix.

Are you at a maintenance dose? Stalling at 1 mg when the maintenance dose is higher isn't drug failure — it's an incomplete titration. Finishing the ladder is the obvious first move, and it's your prescriber's call.

Protein and resistance training. Losing muscle alongside fat lowers your energy requirement, which makes the plateau worse and self-reinforcing. Adequate protein plus resistance work is the evidence-backed lever for preserving lean mass during weight loss — and unlike a drug switch, it changes the thing that's actually working against you. Start with your protein floor and how to split it across meals.

Has intake drifted? As side effects fade, appetite partially returns and portions quietly grow. Most people don't notice without measuring. A week of honest logging answers it.

Sleep and stress. Both affect appetite regulation and weight. Neither is fixed by changing molecule.

Other medications. Some cause weight gain or block loss. Worth a medication review before concluding the GLP-1 failed.

Is the scale the wrong instrument? Flat weight with improving body composition is progress being measured badly — the case for tracking more than weight.

What "maintenance dose" means for each drug

Worth knowing, because "I'm on the highest dose" often turns out not to be true.

Semaglutide and tirzepatide each have their own approved ladders, with different maintenance doses for weight management versus type 2 diabetes, and different maximum doses. The rungs are not interchangeable between drugs and there is no equivalence table — 1 mg of semaglutide does not "equal" any particular dose of tirzepatide.

If you're unsure where you sit on your own ladder, the titration planner maps the approved steps, and the dose conversion guide explains why cross-drug conversion charts are misleading.

The practical constraints

Efficacy data rarely decides this in practice. What usually does:

Coverage. Whether your insurer or health system covers tirzepatide for weight management, and on what terms.

Indication. Treatment for type 2 diabetes and treatment for obesity follow different approval and reimbursement paths, and the same molecule has different brand names for each.

Supply. Both molecules have had periods of constrained availability.

Tolerability. Some people simply tolerate one better. That only becomes apparent after trying.

The return journey. If the switch doesn't work, going back means titrating again. It's not a free experiment in either direction.

None of this argues against switching. It argues for going in with the full picture rather than a single trial statistic.

Frequently asked questions

Is Mounjaro more effective than Ozempic? In SURMOUNT-5 (NEJM, 72 weeks, 751 adults with obesity without type 2 diabetes): 20.2% weight reduction on tirzepatide versus 13.7% on semaglutide. That compares the drugs as treatments, not as a switch.

Does switching break a plateau? Less well studied than the head-to-head comparison. Some people resume losing; it isn't guaranteed.

What dose do I start on? Tirzepatide starts at 2.5 mg weekly regardless of your semaglutide dose. No conversion factor exists.

Is a plateau normal? Yes. Energy requirements fall as weight falls, so loss slows. A flattening curve is expected.

How long before considering a change? Short stalls often resolve. Prescribers generally want sustained lack of progress at a maintenance dose with other causes ruled out.

Can I take both together? No. Any transition is managed by your prescriber.

Bring data, not impressions

Project your trajectory → · Check your protein floor → · All Tiro GLP-1 tools →

Tiro is a tracker and companion app. It is not a treatment, does not diagnose, and does not replace your prescriber. SURMOUNT-5 results as published in the New England Journal of Medicine.